Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

NCT00403325 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Central Serous Chorioretinopathy

Interventions

DRUG: rhuFab V2 [ranibizumab] ( Lucentis )

Sponsor

Vitreous -Retina- Macula Consultants of New York

Collaborators

[object Object]